Teclistamab (2) – Tecvayli®
Multiple myeloma, relapsed or refractory, following at least one prior line of treatment, in combination with daratumumab
Characteristics
| Start date | 01.10.2026 |
|---|---|
| Resolution | n.d. – active procedure |
| INN | Teclistamab |
| Brand name | Tecvayli® |
| Pharm. company | Johnson & Johnson |
| G-BA Procedure ID | D-xxxx |
| Therapeutic area | Oncological diseases |
| Reason for procedure | not completed: start postponed |
Associated procedures
<< List of all resolutions